^
BIOMARKER:

KRAS mutation + STK11 mutation

i
Other names: Serine/Threonine-Protein Kinase 11, Liver Kinase B1, Serine/Threonine-Protein Kinase LKB1, Polarization-Related Protein LKB1, STK11, Serine/Threonine Kinase 11, Serine/Threonine-Protein Kinase STK11, Renal Carcinoma Antigen NY-REN-19, KRAS, KRAS1, KRAS2, Kirsten rat sarcoma viral oncogene homolog
Entrez ID:
Related biomarkers:
KRAS mutation + STK11 mutation
LUAD
Immunotherapy
Resistant: C3 – Early Trials
J Thorac Oncol - 4 weeks
KRAS mutation + STK11 mutation
NSCLC
Immunotherapy
Resistant: C3 – Early Trials
KRAS mutation + STK11 mutation
NSCLC
PD-L1 inhibitor
Sensitive: C3 – Early Trials
KRAS mutation + STK11 mutation
NSCLC
CI-1040
Sensitive: D – Preclinical
KRAS mutation + STK11 mutation
NSCLC
pembrolizumab + quaratusugene ozeplasmid
Sensitive: D – Preclinical